Absci Announces Interim Phase 1 Data From Its Trial Of ABS-201, An Investigational Anti-Prolactin Receptor Antibody; Study Medication Appears Well Tolerated, With Favorable Safety Data Across All Blinded Single Ascending Dose Cohorts

Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period

First multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic alopecia (AGA) participants has been initiated

Interim proof-of-concept data anticipated in the second half of 2026, with full proof-of-concept data in early 2027